General description

A cell-permeable 8-hydroxyquinoline compound that is reported to inhibit nuclear E2F complexes DNA binding activity (IC₅₀ = 30 µM) and downregulate E2F expression in the melanoma cell line A375, resulting in eventual apoptosis induction without upregulating p53 expression as commonly seen with traditional chemotherapeutic agents, such as Cisplatin (Cat. No. 232120), doxorubicin (Cat. No. 324380), and VP-16 (Cat. No. 341205).

A cell-permeable 8-hydroxyquinoline compound that is reported to inhibit nuclear E2F complexes DNA binding activity (IC₅₀ = 30 µM) and downregulate E2F expression in the melanoma cell line A375, resulting in eventual apoptosis induction without upregulating p53 expression as commonly seen with traditional chemotherapeutic agents, such as Cisplatin (Cat. No. 232120), doxorubicin (Cat. No. 324380), and VP-16 (Cat. No. 341205).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Ma, Y., et al. 2008. Cancer Res.68, 6292.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)